Dai-kenchu-to (DKT) is a Japanese herbal medicine used to treat various illnesses. The herb helps prevent the gut from inflammatory bowel disease (IBD).
- Dai-kenchu-to (DKT) is a Japanese herbal medicine used to treat various illnesses
- Imbalance in the gut microbiota can cause colitis, an inflammation of the inner lining of the colon
- The herb helps prevent the gut from inflammatory bowel disease (IBD)
Prevalence has doubled over the last 20 years, and it’s currently a global health concern, particularly in Europe and North America. Although treatments are numerous, they are only partially effective. This has led some researchers to take a closer look at traditional herbal medicines that originated in China, and are now commonly used in Japan and other Asian countries.
What is Dai-Kenchu-to?
Dai-kenchu-to (DKT) is a formula containing specific amounts of ginger, pepper, ginseng, and maltose, and is one of 148 herbal medicines called Kampo, which have been developed in Japan and are often prescribed by doctors to treat a variety of illnesses.Previous research has hinted that DKT might be useful for treating colitis, but evidence, particularly at the molecular level, has been lacking. Thus, Shi and the team of researchers at RIKEN IMS led by Naoko Satoh-Takayama conducted a detailed examination of its effects on a mouse model of colitis.
Japanese Herb for IBD: Clinical Studies
Colitis was induced in mice using dextran sodium sulfate, which is toxic to the cells that line the colon. When these mice were given DKT, their body weights remained normal, and they had lower clinical scores for colitis. Additional analysis revealed much less damage to the cells lining the colon. Having thus shown that DKT does indeed help protect against colitis, the researchers proceeded to analyze the gut microbiome of the mice and the expression levels of anti-inflammatory immune cells.Treating the model mice with DKT restored much of these missing bacteria—particularly those from the genus Lactobacillus—and levels of propionate were normal.
When the team looked at innate intestinal immune cells, they found that levels of a type called ILC3 were lower in the untreated colitic mice than in the DKT-treated colonic mice, and that mice engineered to lack ILC3 suffered more and could not benefit from DKT treatment. This means that ILC3s are critical for protecting against colitis and that DKT works by interacting with them. Lastly, qPCR analysis indicated that these important immune cells had receptors for propionate, called GPR43, on their surface.
“Dai-kenchu-to is commonly prescribed to prevent and treat gastrointestinal diseases, as well as for reducing intestinal obstruction after colorectal cancer surgery,” says Satoh-Takayama. “Here we have shown that it can also alleviate intestinal diseases like colitis by rebalancing Lactobacillus levels in the gut microbiome. This likely helps reduce inflammatory immune responses by promoting the activity of type 3 innate lymphoid cells.”
Source-Eurekalert